ATI RN
ATI Pharmacology Proctored Exam 2023
1. A healthcare professional is educating a client who is starting therapy with topotecan. Which of the following findings should the professional instruct the client to report?
- A. Hair loss
- B. Fatigue
- C. Sore throat
- D. Red urine
Correct answer: C
Rationale: The correct answer is C: 'Sore throat.' Clients starting therapy with topotecan should be instructed to report a sore throat because it can indicate an infection due to the immunosuppressive effects of the medication. Infections can be serious in clients undergoing chemotherapy, so early detection and treatment are crucial to prevent complications. Choices A, B, and D are incorrect because while they are potential side effects of topotecan, they are usually not as immediately concerning as a sore throat, which could signal a serious infection requiring prompt attention.
2. A client has a prescription for Clindamycin. Which of the following instructions should the nurse include?
- A. Take the medication with a full glass of water.
- B. Avoid taking the medication with food.
- C. Discontinue the medication if diarrhea occurs.
- D. Expect to have increased appetite while taking this medication.
Correct answer: A
Rationale: The correct instruction for a client taking Clindamycin is to take the medication with a full glass of water. Clindamycin can cause esophageal irritation, so taking it with a full glass of water helps minimize this risk. Avoiding taking the medication with food is not necessary. If diarrhea occurs, clients should not discontinue the medication without consulting their healthcare provider. Clindamycin is not known to cause increased appetite.
3. A client asks the nurse how Rituximab works, which the client is receiving to treat Non-Hodgkin's Leukemia. Which of the following should the nurse include?
- A. Blocks hormone receptors
- B. Increases immune response
- C. Binds with specific antigens on tumor cells
- D. Stops DNA replication during cell division
Correct answer: C
Rationale: Rituximab is a monoclonal antibody that binds with specific antigens on B-lymphocytes, leading to the destruction of cancer cells. In the context of Non-Hodgkin's Leukemia, Rituximab targets and destroys cancerous B-lymphocytes, which helps in treating the disease. Choices A, B, and D are incorrect. Rituximab does not block hormone receptors, increase immune response, or stop DNA replication during cell division. The primary mode of action of Rituximab is its binding with specific antigens on tumor cells, specifically B-lymphocytes, to elicit an immune response against cancerous cells.
4. A client has a new prescription for Losartan. Which of the following laboratory values should the nurse monitor?
- A. Serum potassium
- B. Serum sodium
- C. Serum calcium
- D. Serum magnesium
Correct answer: A
Rationale: Corrected Rationale: Losartan, an angiotensin II receptor blocker (ARB), can cause hyperkalemia. The nurse should monitor the client's serum potassium levels closely because Losartan can increase potassium levels, potentially leading to serious complications such as arrhythmias. Monitoring serum sodium, calcium, or magnesium levels is not typically necessary when a patient is prescribed Losartan, as these values are not directly affected by this medication.
5. A client has a new prescription for a Fentanyl transdermal patch. Which of the following instructions should the nurse include?
- A. Apply the patch to a non-hairy area.
- B. Change the patch every 72 hours.
- C. Avoid exposure to heat sources.
- D. Do not cut the patch to adjust the dosage.
Correct answer: C
Rationale: The correct instruction the nurse should include for a client using a Fentanyl transdermal patch is to avoid exposure to heat sources. Heat can increase the absorption of the medication, potentially causing an overdose. Instructing the client to avoid heat sources is crucial to ensure their safety and the effectiveness of the medication. Choices A, B, and D are incorrect because applying the patch to a non-hairy area, changing it every 72 hours, and not cutting the patch are general guidelines for using transdermal patches but do not specifically address the unique risks associated with Fentanyl patches.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access